A combination of remdesivir and a concentrated solution of antibodies did not work well in people hospitalized with COVID-19, according to a newly published study.
The clinical trial tested remdesivir, an antiviral from Gilead Sciences, combined with anti-coronavirus hyperimmune intravenous immunoglobulin (hIVIG), the concentrated solution, but the combination did not significantly improve favorable outcomes among the patients, researchers reported in The Lancet.
